Literature DB >> 20138985

Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1.

Emmani B M Nascimento1, Marieke Snel, Bruno Guigas, Gerard C M van der Zon, Jan Kriek, J Antonie Maassen, Ingrid M Jazet, Michaela Diamant, D Margriet Ouwens.   

Abstract

Type 2 diabetes is associated with alterations in protein kinase B (PKB/Akt) and mammalian target of rapamycin complex 1 (mTORC1) signalling. The proline-rich Akt substrate of 40-kDa (PRAS40) is a component of mTORC1, which has a regulatory function at the intersection of the PKB/Akt and mTORC1 signalling pathway. Phosphorylation of PRAS40-Thr246 by PKB/Akt, and PRAS40-Ser183 and PRAS40-Ser221 by mTORC1 results in dissociation from mTORC1, and its binding to 14-3-3 proteins. Although all phosphorylation sites within PRAS40 have been implicated in 14-3-3 binding, substitution of Thr246 by Ala alone is sufficient to abolish 14-3-3 binding under conditions of intact mTORC1 signalling. This suggests that phosphorylation of PRAS40-Thr246 may facilitate efficient phosphorylation of PRAS40 on its mTORC1-dependent sites. In the present study, we investigated the mechanism of PRAS40-Ser183 phosphorylation in response to insulin. Insulin promoted PRAS40-Ser183 phosphorylation after a euglycaemic-hyperinsulinaemic clamp in human skeletal muscle. The insulin-induced PRAS40-Ser183 phosphorylation was further evidenced in vivo in rat skeletal and cardiac muscle, and in vitro in A14 fibroblasts, 3T3L1 adipocytes and L6 myotubes. Inhibition of mTORC1 by rapamycin or amino acid deprivation partially abrogated insulin-mediated PRAS40-Ser183 phosphorylation in cultured cell lines. However, lowering insulin-induced PRAS40-Thr246 phosphorylation using wortmannin or palmitate in cell lines, or by feeding rats a high-fat diet, completely abolished insulin-mediated PRAS40-Ser183 phosphorylation. In addition, replacement of Thr246 by Ala reduced insulin-mediated PRAS40-Ser183 phosphorylation. We conclude that PRAS40-Ser183 is a component of insulin action, and that efficient phosphorylation of PRAS40-Ser183 by mTORC1 requires the phosphorylation of PRAS40-Thr246 by PKB/Akt. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138985     DOI: 10.1016/j.cellsig.2010.02.002

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  41 in total

1.  Functional Proteomics Identifies Acinus L as a Direct Insulin- and Amino Acid-Dependent Mammalian Target of Rapamycin Complex 1 (mTORC1) Substrate.

Authors:  Jennifer Jasmin Schwarz; Heike Wiese; Regine Charlotte Tölle; Mostafa Zarei; Jörn Dengjel; Bettina Warscheid; Kathrin Thedieck
Journal:  Mol Cell Proteomics       Date:  2015-04-23       Impact factor: 5.911

2.  Kinetic Modeling and Analysis of the Akt/Mechanistic Target of Rapamycin Complex 1 (mTORC1) Signaling Axis Reveals Cooperative, Feedforward Regulation.

Authors:  Anisur Rahman; Jason M Haugh
Journal:  J Biol Chem       Date:  2017-01-09       Impact factor: 5.157

Review 3.  Cardiovascular disease and mTOR signaling.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Kenneth Maiese
Journal:  Trends Cardiovasc Med       Date:  2011-07       Impact factor: 6.677

4.  Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism.

Authors:  Antonella Caccamo; Monica A Maldonado; Smita Majumder; David X Medina; Walter Holbein; Andrea Magrí; Salvatore Oddo
Journal:  J Biol Chem       Date:  2011-01-25       Impact factor: 5.157

5.  Lys05 - A Promising Autophagy Inhibitor in the Radiosensitization Battle: Phosphoproteomic Perspective.

Authors:  Martin Ondrej; Lucie Cechakova; Ivo Fabrik; Jana Klimentova; Ales Tichy
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

Review 6.  The critical role of Akt in cardiovascular function.

Authors:  Prasanna Abeyrathna; Yunchao Su
Journal:  Vascul Pharmacol       Date:  2015-05-27       Impact factor: 5.773

Review 7.  Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Prog Neurobiol       Date:  2012-08-15       Impact factor: 11.685

Review 8.  Targeting disease through novel pathways of apoptosis and autophagy.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang
Journal:  Expert Opin Ther Targets       Date:  2012-08-27       Impact factor: 6.902

9.  TGFBI (βIG-H3) is a diabetes-risk gene based on mouse and human genetic studies.

Authors:  Bing Han; Hongyu Luo; John Raelson; Jie Huang; Yun Li; Johanne Tremblay; Bing Hu; Shijie Qi; Jiangping Wu
Journal:  Hum Mol Genet       Date:  2014-04-11       Impact factor: 6.150

Review 10.  mTOR: on target for novel therapeutic strategies in the nervous system.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang
Journal:  Trends Mol Med       Date:  2012-12-19       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.